NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
Clinical Trials
109 trialsNCT06859424 2026-03-17
ACCELERATE
Center for International Blood and Marrow Transplant Research
Phase 2 Recruiting
NCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT06773936 2026-03-04
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Enrolling by invitation
NCT04115631 2026-03-02
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05289687 2026-03-02
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group
Phase 2 Recruiting
NCT02981628 2026-02-23
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 2 Recruiting
NCT05998642 2026-02-12
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07341191 2026-02-12
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
Phase 2 Not yet recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT05180097 2026-02-02
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT05633615 2026-02-02
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Phase 2 Recruiting
NCT05761171 2025-12-22
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
Phase 2 Active not recruiting
NCT05890352 2025-10-20
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
SWOG Cancer Research Network
Phase 2 Recruiting
NCT07209059 2025-10-06
FINISH-HL
National Research Center for Hematology, Russia
Phase 2 Recruiting
NCT02793544 2025-08-06
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
Phase 2 Completed
NCT00812669 2025-07-08
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
Cancer Trials Ireland
Phase 2 Completed
NCT01415752 2025-04-08
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06764017 2025-03-19
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
First Affiliated Hospital of Ningbo University
Phase 2 Recruiting
NCT06758037 2025-03-18
HiR+X
First Affiliated Hospital of Ningbo University
Phase 2 Recruiting
NCT03443128 2025-02-13
Vinorelbine for Recurrent ALCL-2017
Children's Cancer Group, China
Phase 2 Completed
NCT03615664 2025-01-16
BURGUND
Polish Lymphoma Research Group
Phase 2 Completed
NCT03293173 2024-06-21
Bio-CHIC
Nordic Lymphoma Group
Phase 2 Active not recruiting
NCT04128072 2024-04-05
MOGAT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT03357224 2024-02-22
PARCT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT04218825 2023-11-09
REACH
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT01696461 2023-09-14
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Center for International Blood and Marrow Transplant Research
Phase 2 Completed
NCT02340780 2023-08-22
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Canadian Cancer Trials Group
Phase 2 Completed
NCT03229382 2023-08-16
OPERA-PLRG10
Polish Lymphoma Research Group
Phase 2 Terminated
NCT00030875 2023-08-04
Bortezomib in Treating Patients With Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00377052 2023-08-04
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01627054 2023-08-04
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
Canadian Cancer Trials Group
Phase 2 Completed
NCT01652144 2023-08-04
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01399372 2023-07-20
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00003910 2023-07-05
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00335140 2023-07-03
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00074282 2023-06-29
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00274924 2023-06-29
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01216683 2023-06-29
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01390584 2023-06-29
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00057954 2023-06-28
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT01013961 2023-06-28
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT00003808 2023-06-22
Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00006390 2023-06-22
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003615 2023-06-15
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05660993 2022-12-21
Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT01775475 2022-10-10
Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
AIDS Malignancy Consortium
Phase 2 Completed
NCT03397953 2022-07-26
Vinorelbine for Recurrent ACLC
Children's Cancer Group, China
Phase 2 Completed
NCT01481272 2021-12-27
PLRG8
Polish Lymphoma Research Group
Phase 2 Completed